Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)

Background
The National Cancer Institute (NCI) aims to support the AIDS Malignancy Consortium (AMC) through this Notice of Funding Opportunity (NOFO). The AMC is designed to enhance cooperative research efforts in addressing HIV-associated malignancies, which are a significant public health issue globally.

The initiative focuses on developing clinical interventions, therapeutics, and management strategies for malignancies in people living with HIV (PWH). It also investigates the biology of these malignancies within clinical trials. The AMC will manage international issues related to HIV-associated cancers and facilitate the distribution of biological specimens for ongoing research.

Grant Details
The AMC must include several functional units: a Coordination Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center. The consortium will conduct research in areas such as Kaposi Sarcoma, Hematologic Malignancies, HPV-associated cancers, and Solid Tumors in PWH.

Responsibilities include designing and evaluating clinical interventions for cancer prevention and treatment in PWH, developing effective therapeutics, conducting correlative studies related to pathogenesis and pharmacokinetics of anticancer/antiviral interactions, and ensuring all clinical trials are accessible to diverse racial/ethnic groups. The AMC is expected to collaborate with local patient advocacy groups and NIH-supported networks to achieve its goals.

Eligibility Requirements
Only current recipients of the AIDS Malignancy Consortium supported under RFA-CA-19-056 are eligible to apply. Non-domestic entities are not eligible. Each institution can submit only one application.

Period of Performance
The project period must be proposed for 5 years.

Grant Value
NCI intends to commit $18.1 million in FY 2025 for one award, with a total 5-year cost not exceeding $97 million.

Place of Performance
The grant activities will be conducted at domestic and international Clinical Trial Sites reflecting areas with high HIV/AIDS disease burden.